Insider

Doximity, Inc.

DOCS Information Technology · 6 analyses · 2 expectations tracked

Doximity reported $175M in revenue (+3.6% YoY), compared with a +20.6% median across covered Information Technology peers. Insider tracks 2 open management expectations for this company. 4 insider sales recorded.

Mentioned in recent filings: Tariffs

What changed

What changed

Doximity rolls out AI tools at major medical systems

NewYork-Presbyterian, Columbia University and Weill Cornell Medicine began deploying Doximity's Doximity Ask and Doximity Scribe artificial intelligence tools within their Epic electronic health record systems. This integration expands clinician capabilities for decision-making and medical documentation across these large academic institutions.

· Doximity, Inc.
What changed

Doximity expands clinical AI reach and updates Ask platform

Doximity, Inc. reported positive research results for its AI tool, Doximity Ask, which will now integrate with UpToDate medical content. The developer also expanded its Clinical AI Suite deployment to more than 165 health systems, covering half of the top 20 U.S. hospitals.

· Doximity, Inc.
Show all articles (6)
Deals & ownership

Doximity insiders receive shares and file sale plans

Between September 16 and October 14, 2026, Doximity, Inc. insiders executed several stock transactions, including a major award to the president and planned sales by directors. On September 24, president Steven L. Zatz received 152,427 shares, while directors Phoebe L. Yang Watkin and Kira Wampler sold portions of their stakes under pre-approved trading plans.

· Doximity, Inc.

Company history

October 2026

Doximity, Inc.: 12 recorded developments from 4 official sources in 2026-10.

  • 2026-09-16: Summary: S (open market or private sale): 1 transaction(s) on 2026-09-15, 2,077 disposed, total value 54,043.54 USD at a weighted average price of 26.02 USD; owned after the last one: 96,045 Source
  • 2026-10-16: Summary: S (open market or private sale): 1 transaction(s) on 2026-10-14, 2,613 disposed, total value 80,166.84 USD at a weighted average price of 30.68 USD; owned after the last one: 101,432 Source
  • 2026-10-19: Doximity's Clinical AI Suite has been deployed across more than 150 health systems, including eight of the top 20 hospitals in the United States. Source
  • 2026-10-19: Doximity Ask outperformed GPT-5.6 Sol, Claude Fable 5, and other leading frontier AI models in a study conducted by the ARISE team. Source
  • 2026-10-19: Doximity Ask is described as a HIPAA-compliant AI platform where practicing physicians review AI-generated answers for accuracy and bias. Source
  • 2026-10-20: Doximity and Wolters Kluwer Health formed a partnership to integrate UpToDate clinical content into Doximity Ask. Source
  • 2026-10-20: Doximity's Clinical AI Suite, which includes Ask, Scribe, and Dialer, is deployed at more than 165 health systems, including 10 of the nation's top 20 hospitals. Source
  • 2026-10-20: Doximity Ask was ranked top among U.S. clinical AI models in the NOHARM study conducted by researchers at Stanford and Harvard. Source
  • 2026-10-20: Doximity and Wolters Kluwer Health entered a partnership to integrate UpToDate's clinical content into Doximity Ask. Source
  • 2026-10-20: Doximity's Clinical AI Suite, which includes Ask, Scribe, and Dialer, is deployed at more than 165 health systems. Source
  • 2026-10-20: Doximity's PeerCheck program utilizes more than 12,000 cited physician experts to evaluate and improve Doximity Ask's outputs. Source
  • 2026-10-20: In the NOHARM study by researchers at Stanford and Harvard, Doximity Ask ranked as a top U.S. clinical AI model. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 5, 2026. SEC

LatestEarlierChange
Revenue quarter$175M$169M+3.6%
Operating income quarter$43.9M$63.7M-31.0%
Net income quarter$34.7M$62.1M-44.0%
Diluted EPS quarter$0.18$0.31-41.9%
Operating cash flow year to date$135M$156M-13.3%
Cash and cash equivalents balance$219M$219M-0.3%

Next results expected around February 4, 2027 (estimate: the quarter ending about December 30, 2026 plus the 36 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $M

168.6Q3 '2547.4%138.3Q4 '25*35.2%145.9Q1 '2637.4%168.5Q2 '2637.8%185.1Q3 '2638.9%145.4Q4 '26*17.1%156.6Q1 '2721.5%174.5Q2 '2725.2%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 89 covered companies in Information Technology (median revenue change +20.6% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Doximity, Inc. DOCS$175M+3.6%25.2%
Apple Inc. AAPL$479B+15.1%33.0%
Micron Technology Inc MU$133B+256.3%74.6%
NVIDIA Corp NVDA$96.2B+105.9%66.2%
Microsoft Corp MSFT$92.3B+18.8%49.8%
Accenture plc ACN$74.2B+6.5%15.4%
Dell Technologies Inc. DELL$47B+57.7%11.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • The company provided guidance for the fiscal third quarter ending December 31, 2026, with revenue between $195 million and $196 million and Adjusted EBITDA between $102.5 million and $103.5 million.

    Said November 5, 2026 · Period named: fiscal third quarter ending December 31, 2026 · Source · Our article

    Not yet checked against later reports.

  • The company updated guidance for the fiscal year ending March 31, 2027, with revenue between $678 million and $683 million and Adjusted EBITDA between $317 million and $325 million.

    Said November 5, 2026 · Period named: fiscal year ending March 31, 2027 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 16, 2026Siddharth SitaramSale 10b5-1 plan notice filed2,523$33.31$84,041SEC
November 5, 2026Timothy S CabralSale 10b5-1 plan10,721$35.00$375,235SEC
November 5, 2026Timothy Stephen CabralPlanned sale 10b5-1 plan10,721—$375,235SEC
November 2, 2026Kira Scherer WamplerSale 10b5-1 plan2,000$32.89$65,780SEC
November 2, 2026Kira WamplerPlanned sale 10b5-1 plan2,000—$65,780SEC
October 14, 2026Siddharth SitaramSale 10b5-1 plan notice filed2,613$30.68$80,167SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock14,354,834$406,816,001+0.3%Q3 2026
D. E. Shaw & Co.6,214,936$176,131,286+4.9%Q3 2026
Two Sigma Investments4,136,364$117,224,556-11.0%Q3 2026
State Street4,135,771$117,207,750-1.8%Q3 2026
Wellington Management3,369,810$95,500,416+7.5%Q3 2026
Renaissance Technologies2,684,449$76,077,285-5.9%Q3 2026
Citadel Advisors2,454,185$69,551,603+57.2%Q3 2026
Norges Bank (Norway's sovereign fund)1,889,029$39,178,461—Q2 2026
Fidelity (FMR)1,271,361$36,030,358+3,349.9%Q3 2026
Millennium Management966,081$27,378,736-53.3%Q3 2026
Bridgewater Associates13,633$386,359-89.6%Q3 2026
T. Rowe Price130,678$3,704+0.2%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.